GBI Research

Report: Healthcare companies must embrace new funding sources

Tuesday, November 29, 2016

Although the life sciences industry remains an attractive investment area, the healthcare sector has seen a decline in venture investments, particularly for early-stage investments, as pricing pressures, stringent regulations, rising development costs, reimbursement issues, and declining R&D productivity have proved significant barriers, said business intelligence provider GBI Research.

[Read More]

Report: Breast cancer has over 1,000 drugs in development

Tuesday, March 1, 2016

The breast cancer treatment pipeline’s exceptional levels of activity and innovation, with a staggering 1,050 drugs in active development across all stages and 347 first-in-class programs, may significantly alter the clinical and commercial landscape of the disease market over the next decade, according to business intelligence provider GBI Research.

[Read More]